Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction.
Paulo R Rizzo GenestretiRemo H M FurtadoRocío SalsosoTalia F DalçóquioAndre FranciFernando R MenezesCesar CaporrinoAline G FerrariCarlos A K NakashimaMarco A Scanavini FilhoFelipe G LimaRoberto R C V GiraldezLuciano M BaracioliJose C NicolauPublished in: Journal of clinical medicine (2022)
DPP4 inhibitor did not reduce platelet aggregation among patients with type 2 diabetes hospitalized with AMI. Moreover, the use of DPP-4i did not show an increase in BNP levels or in the incidence of cardiac adverse events. These findings suggests that DPP-4i could be an option for management of T2DM patients with acute MI.